MergerJul 31, 2026, 04:38 PM
Galera Completes $350M PIPE Financing; Mergers Expected to Close Aug 3
AI Summary
Galera Therapeutics, Inc. announced the completion of its Concurrent PIPE Financing, raising approximately $350.0 million through the sale of Series C Non-Voting Convertible Preferred Stock. This financing is in connection with the previously disclosed merger agreement involving Galera, Obsidian Therapeutics, Inc., and Gazelle Parent, Inc., which is expected to close on August 3, 2026. Additionally, Galera declared a Pre-Closing Distribution of contingent value rights (CVRs) to its common stockholders, with a record date of July 31, 2026, and an expected distribution date of August 6, 2026.
Key Highlights
- Galera completed Concurrent PIPE Financing, raising approximately $350.0 million.
- Shares of Series C Preferred Stock were sold in private placements.
- Merger Agreement involves Galera, Obsidian Therapeutics, and Gazelle Parent, Inc.
- Mergers are expected to close on August 3, 2026.
- Galera declared a Pre-Closing Distribution of contingent value rights (CVRs) to common stockholders.
- CVRs entitle holders to contingent cash payments from assets like tilarganine, rucosopasem, and avasopasem.
- Record date for Pre-Closing Distribution is July 31, 2026.
- Distribution date for CVRs is expected on August 6, 2026.
Price Impact
More from GRTX